

## **WuXi Biologics launches new GMP commercial drug product facility in China**

01 November 2021 | News

### **Increases up to 60 million vials for commercial drug production per year**

WuXi Biologics has successfully launched the GMP operation of its new drug product facility located in Wuxi, China, which is the eighth operational drug product facility in the global network of WuXi Biologics.

The 12,000m<sup>2</sup> drug product facility, called DP2, features a state-of-the-art isolator filling line for the continuous high-speed production of wide size range – from 2R to 50R of liquid and 20m<sup>2</sup>/40m<sup>2</sup> of lyophilization.

Leveraging its innovative design, the facility can switch rapidly between different specifications to maximize its filling efficiency, providing flexible drug product manufacturing solutions to meet customers' needs. DP2 will increase up to 60 million vials for commercial drug production of biologics per year.

This facility serves as an example of WuXi Biologics' implementation of single-use technology as it utilizes disposable peristaltic pump filling systems and sterile filtration systems in pre-use post sterilization integrity testing (PUPSIT), which meet current and evolving global regulatory requirements.

In addition, WuXi Biologics has also launched the GMP operation of a new Drug Product Packaging Center (DPPC) which includes the company's first fully automated vial packaging line.